These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dendritic cell immunotherapy: mapping the way. Figdor CG; de Vries IJ; Lesterhuis WJ; Melief CJ Nat Med; 2004 May; 10(5):475-80. PubMed ID: 15122249 [TBL] [Abstract][Full Text] [Related]
5. Optimal control in a model of dendritic cell transfection cancer immunotherapy. Castiglione F; Piccoli B Bull Math Biol; 2006 Feb; 68(2):255-74. PubMed ID: 16794930 [TBL] [Abstract][Full Text] [Related]
6. Optimizing dendritic cell-based immunotherapy for cancer. Zhong H; Shurin MR; Han B Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749 [TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines: a critical review on clinical impact. Bitton RJ Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of cancer using dendritic cells. Morse MA; Lyerly HK Cytokines Cell Mol Ther; 1998 Mar; 4(1):35-44. PubMed ID: 9557215 [TBL] [Abstract][Full Text] [Related]
9. Cellular immunotherapy with dendritic cells in cancer: current status. Nencioni A; Brossart P Stem Cells; 2004; 22(4):501-13. PubMed ID: 15277696 [TBL] [Abstract][Full Text] [Related]
11. Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. O'Neill D; Bhardwaj N Methods Mol Med; 2005; 109():1-18. PubMed ID: 15585909 [TBL] [Abstract][Full Text] [Related]
12. Personalized cancer vaccines. Jain KK Expert Opin Biol Ther; 2010 Dec; 10(12):1637-47. PubMed ID: 20979567 [TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cell-based cellular vaccine: An efficient immunotherapeutic strategy for human malignancies. Zhou L; Xiang J; Chen X Med Hypotheses; 2011 Feb; 76(2):206-7. PubMed ID: 20974521 [TBL] [Abstract][Full Text] [Related]
15. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer]. Punt CJ; de Vries IJ; Mulders PF; Adema GJ; Figdor CG Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2408-14. PubMed ID: 10608974 [TBL] [Abstract][Full Text] [Related]
16. DNA and RNA modified dendritic cell vaccines. Morse MA; Lyerly HK World J Surg; 2002 Jul; 26(7):819-25. PubMed ID: 11948364 [TBL] [Abstract][Full Text] [Related]
17. [The role of immunotherapy in the treatment of patients with hematologic neoplasms]. Rukavitsyn OA Vopr Onkol; 2002; 48(2):186-92. PubMed ID: 12227066 [No Abstract] [Full Text] [Related]
18. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Schultze JL; Grabbe S; von Bergwelt-Baildon MS Trends Immunol; 2004 Dec; 25(12):659-64. PubMed ID: 15530836 [TBL] [Abstract][Full Text] [Related]
19. Developing enabling technologies for the success of cancer immunotherapy. Sznol M Curr Opin Investig Drugs; 2004 Dec; 5(12):1239-42. PubMed ID: 15648943 [No Abstract] [Full Text] [Related]
20. Therapeutic cancer vaccines: an emerging treatment option. King SE Clin J Oncol Nurs; 2004 Jun; 8(3):271-8. PubMed ID: 15208821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]